| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |